S. Panchal

发表

Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort study

A. Noor, Y. Bombard, S. Horsburgh, 2020, Journal of Medical Genetics.

Incidental findings from cancer next generation sequencing panels

P. Ainsworth, S. Armel, B. Sadikovic, 2021, NPJ genomic medicine.

Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery

Y. Bombard, E. Seto, A. Eisen, 2022, BMJ Open.

Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer

F. O'Malley, J. Crook, S. Panchal, 2009, Nature Reviews Clinical Oncology.

A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings

Y. Bombard, A. Eisen, S. Armel, 2022, Human Genetics.

Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.

O. Olopade, B. Karlan, P. Møller, 2018, International journal of epidemiology.

Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

Stephanie A Cohen, O. Olopade, B. Karlan, 2021, Breast Cancer Research and Treatment.

A Review of Genetic Counseling for Charcot Marie Tooth Disease (CMT)

S. Feely, C. Siskind, J. Dalton, 2013, Journal of Genetic Counseling.

Development of patient “profiles” to tailor counseling for incidental genomic sequencing results

Y. Bombard, A. Eisen, R. Kim, 2019, European Journal of Human Genetics.

An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer

R. Kim, N. Watkins, S. Panchal, 2019, Expert review of anticancer therapy.

Predictors of mammographic density among women with a strong family history of breast cancer

M. Yaffe, J. Knight, A. Eisen, 2019, BMC Cancer.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Stephanie A Cohen, F. Couch, O. Olopade, 2016, British Journal of Cancer.

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study

Charis Eng, Fergus Couch, Kevin Sweet, 2013, British Journal of Cancer.

Incidental findings from cancer next generation sequencing panels

P. Ainsworth, S. Armel, B. Sadikovic, 2021, npj Genomic Medicine.

The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care

A. Laupacis, C. Earle, Y. Bombard, 2021, Genetics in Medicine.

Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial

S. Scherer, A. Laupacis, C. Earle, 2019, Genetics in Medicine.

Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial

A. Laupacis, Y. Bombard, K. Offit, 2019, BMJ Open.

Development of patient “profiles” to tailor counseling for incidental genomic sequencing results

Y. Bombard, A. Eisen, R. Kim, 2019, European Journal of Human Genetics.

Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial

A. Laupacis, Y. Bombard, K. Offit, 2018, BMJ Open.

Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation‐positive families?

A. Eisen, S. Narod, P. Ainsworth, 2010, Clinical genetics.

Prognosis of BRCA-associated breast cancer: a summary of evidence

P. Goodwin, S. Panchal, L. Bordeleau, 2009, Breast Cancer Research and Treatment.

An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool

Stephanie A Cohen, A. Troyer, W. Foulkes, 2021, Cancer.

Fine mapping of the Schnyder’s crystalline corneal dystrophy locus

F. Tost, H. Kuivaniemi, G. Tromp, 2004, Human Genetics.

Selecting a BRCA risk assessment model for use in a familial cancer clinic

M. Ennis, S. Panchal, L. Bordeleau, 2008, BMC Medical Genetics.

Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial

S. Scherer, A. Laupacis, C. Earle, 2019, Genetics in Medicine.

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

F. Couch, O. Olopade, P. Møller, 2023, Breast Cancer Research and Treatment.

Quality of life drives patients’ preferences for secondary findings from genomic sequencing

S. Scherer, A. Laupacis, C. Earle, 2020, European Journal of Human Genetics.

Great expectations: patients’ preferences for clinically significant results from genomic sequencing

A. Laupacis, C. Earle, Y. Bombard, 2023, Human Genetics.

Predictors of mammographic density among women with a strong family history of breast cancer

M. Yaffe, J. Knight, A. Eisen, 2019, BMC Cancer.

Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy

B. Clarke, H. Berman, M. Bernardini, 2023, American journal of human genetics.

A model for the return and referral of all clinically significant secondary findings of genomic sequencing

Y. Bombard, A. Eisen, C. Morel, 2023, Journal of Medical Genetics.

Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation‐positive families?

A. Eisen, S. Narod, A. Poll, 2010, Clinical genetics.

A focus group study on breast cancer risk presentation: one format does not fit all

G. Glendon, J. Simard, K. Bouchard, 2012, European Journal of Human Genetics.